Investor relations · Series A 2025
A bootstrapped story
ready to scale.
Truevet was built without external capital from 2014. Profitable since 2018. 100% export revenue across 8 countries. Series A 2025 is the catalyst — not the foundation.
Live traction
01 · The ask
₹25 Cr Series A.
Truevet is raising INR 25 Crore as its first institutional round. The capital is the catalyst for crossing ₹100 Cr in revenue inside four years — with a runway plan that's already validated by our existing export footprint across SEA, MENA, Africa and South Asia.
- 60%Operations & working capitalSupply-chain depth, raw-material inventory, distributor onboarding.
- 19%CapexManufacturing facility upgrade and new product capacity.
- 16%MarketingDigital campaigns, PR, distributor enablement, this platform.
- 10%Employee benefit expensesScientific, regulatory and partnership team buildout.
- 2%Operating expensesInternal process and systems hardening.
02 · Financial projections
From ₹7 Cr to ₹110 Cr.
FY25 baseline → FY29 target. EBITDA turns positive in FY27. Net profit positive in FY28. Hybrid asset-light model keeps capex low relative to revenue, which is what unlocks the operating leverage on the right side of the curve.
| FY | Revenue | Gross profit | EBITDA | PAT |
|---|---|---|---|---|
| FY25 | 7 | 3.5 | -1.3 | -1.4 |
| FY26 | 15 | 8.4 | -1.4 | -4.2 |
| FY27 | 30 | 17.4 | 0.3 | -3 |
| FY28 | 58 | 34.8 | 12.5 | 6.3 |
| FY29 | 110 | 68.2 | 40.2 | 25.9 |
All amounts in INR Crore · Source: Truevet Series A deck 2025
03 · Vision
The five-year exit path.
Truevet's vision is to be the global leader in antibiotic-free animal-health solutions for the markets that matter most — SEA, MENA, Africa, South Asia and LatAm. Five-to-seven years from today we expect either a strategic acquisition by a global animal-health major, or a public listing.
The science is real, the regulatory wind is at our back, the competitor landscape at the top is consolidated and slow, and the mid-market we serve is structurally underserved. What we need now is the capital to scale into it before someone else does.
04 · Leadership
Three people. One thesis.
Founder & CEO
BVSc · 10+ years in animal health
Co-founder & COO
PhD — Manufacturing & Quality · 15+ years in operations
Chief Scientific Officer
PhD — IIT Bombay · PDF — University of Texas (Green Chemistry)
Ten years of evidence.
One conversation away.
The full Series A deck, financial model and data room are available to qualified institutional investors on request.